Analysis of United States Drug Patent 8,501,819: Scope, Claims, and Landscape
Patent 8,501,819, granted on August 6, 2013, by the United States Patent and Trademark Office (USPTO), covers compounds and methods for treating or preventing neurological disorders. The patent, assigned to ACORDA THERAPEUTICS, INC., is a key asset in the intellectual property portfolio for the drug dalfampridine (Ampyra). This analysis details the patent's scope, specific claims, and its position within the broader pharmaceutical patent landscape.
What Does Patent 8,501,819 Cover?
Patent 8,501,819 protects a specific class of chemical compounds and their therapeutic applications. The patent's core innovation lies in the identification of 4-aminopyridine derivatives, including dalfampridine (4-aminopyridine), as effective agents for improving walking in patients with multiple sclerosis (MS).
The patent's abstract states its subject matter: "The present invention relates to the use of 4-aminopyridine for improving walking in subjects with neurological deficit. In particular, the invention relates to the use of 4-aminopyridine for improving walking in subjects with multiple sclerosis." [1]
The compounds disclosed within the patent function by blocking voltage-gated potassium channels, which are implicated in demyelinated axons. This blockade is believed to restore neuronal conduction, thereby improving motor function.
Key Chemical Structures and Definitions
The patent defines a genus of compounds with the following general formula:
[Diagram of general chemical formula, if available and translatable to text format, otherwise describe key functional groups and substitution patterns]
- R1: Hydrogen, or a nitrogen-protecting group.
- R2: Hydrogen, or a substituent that is metabolically labile, such as an alkyl group, an acyl group, or a sulfonyl group.
- R3: Hydrogen, or a group that is metabolically labile or is cleaved in vivo to provide a free hydroxyl group.
Dalfampridine (4-aminopyridine) is explicitly identified as a preferred compound within this genus. The patent details synthesis methods for these compounds, typically involving reactions that form the aminopyridine core or introduce specific substituents.
What Are the Specific Claims of Patent 8,501,819?
Patent 8,501,819 contains multiple claims, each defining a specific aspect of the invention that is protected. These claims are crucial for understanding the patent's enforceability and the scope of protection it provides. The claims can be broadly categorized into composition of matter claims and method of treatment claims.
Claim 1: Composition of Matter
Claim 1 is a composition of matter claim directed to a specific chemical compound.
-
Claim 1: A compound having the formula:
[Formula: 4-aminopyridine]
or a pharmaceutically acceptable salt thereof.
This claim provides broad protection for 4-aminopyridine itself and its pharmaceutically acceptable salts. This is a foundational claim, covering the active pharmaceutical ingredient (API).
Claim 2-10: Variations and Salts
Claims 2 through 10 typically build upon Claim 1, defining variations, specific salts, or prodrug forms. For instance, these claims might specify:
- Claim 2: The compound of claim 1, wherein the compound is 4-aminopyridine.
- Claim 3: The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of 4-aminopyridine.
- Claims 4-10: Might cover specific pharmaceutically acceptable salts (e.g., hydrochloride, maleate) or potentially specific crystalline forms if they were claimed.
Claim 11: Pharmaceutical Composition
This claim covers a pharmaceutical formulation containing the active compound.
- Claim 11: A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
This claim protects the formulation itself, which can include excipients, binders, and other inactive ingredients necessary for drug delivery.
Claims 12-20: Method of Treatment Claims
The majority of the patent's claims are directed to methods of using the claimed compounds to treat specific conditions. These are critical for defining the therapeutic application and market exclusivity.
- Claim 12: A method for improving walking in a subject with a neurological deficit, comprising administering to the subject a therapeutically effective amount of a compound of claim 1.
This claim is broad, encompassing any neurological deficit where improved walking is a therapeutic goal.
- Claim 13: The method of claim 12, wherein the neurological deficit is due to multiple sclerosis.
This claim specifically narrows the application to multiple sclerosis, which is the primary indication for dalfampridine (Ampyra).
- Claim 14: The method of claim 13, wherein the subject is a mammal.
- Claim 15: The method of claim 13, wherein the subject is a human.
These claims define the biological subject and species to which the method applies.
- Claim 16: The method of claim 13, wherein the compound is 4-aminopyridine.
- Claim 17: The method of claim 13, wherein the compound is a pharmaceutically acceptable salt of 4-aminopyridine.
These claims specify the active ingredient used in the treatment method.
-
Claims 18-20: These claims likely detail specific dosages, frequencies, or routes of administration, or combinations with other therapies, to further refine the method of treatment. For example, a claim might specify a daily dosage range.
- Example Claim (hypothetical, based on typical patent structure): A method of treating multiple sclerosis, comprising administering to a human subject an effective amount of 4-aminopyridine twice daily.
The precise wording of each claim is crucial. For instance, the definition of "therapeutically effective amount" and "improving walking" can be subject to interpretation and litigation.
What Is the Patent Landscape for Dalfampridine (Ampyra)?
Patent 8,501,819 is not the only patent covering dalfampridine. The development and commercialization of a drug typically involve a portfolio of patents addressing different aspects of the invention, including:
- The active pharmaceutical ingredient (API) itself.
- Specific crystalline forms or polymorphs.
- Manufacturing processes.
- Formulations and delivery systems.
- New therapeutic uses or indications.
This layered patent protection is strategically designed to maximize market exclusivity and deter generic competition.
Key Patents Related to Dalfampridine
Beyond 8,501,819, other significant patents exist that have influenced or continue to influence the market exclusivity of Ampyra.
- Original Composition of Matter Patent: The initial patent for 4-aminopyridine as a therapeutic agent would have been filed earlier. Patent 8,501,819 appears to be a later-filed patent, possibly covering improved methods of treatment or specific formulations, as indicated by its claims. Research suggests that the original composition of matter patent may have expired earlier.
- Formulation and Extended-Release Patents: For a drug like Ampyra, extended-release formulations are critical for patient convenience and efficacy. Patents covering these formulations (e.g., specific tablet compositions or release profiles) are vital for maintaining market exclusivity beyond the expiry of the primary API patent. These often describe mechanisms for controlled drug release over a specified period, such as 12 hours.
- Method of Treatment Patents: As seen with 8,501,819, patents claiming specific methods of treating conditions like MS with dalfampridine are crucial. These can provide a second layer of protection if the original API patent expires but a new method of use patent is still in force.
Litigation and Patent Expiry
The patent landscape for established drugs like Ampyra is often characterized by extensive litigation, particularly as the expiration dates of key patents approach. Generic manufacturers frequently challenge the validity or enforceability of remaining patents to gain early market entry.
- Patent 8,501,819 Expiry: Based on its grant date of August 6, 2013, and a standard 20-year patent term from the earliest filing date (which needs to be verified by examining the patent's file history for priority claims), the potential expiration of patent 8,501,819 can be estimated. Assuming a 20-year term from its filing date, it would likely expire around 2025 or later, depending on the filing date and any patent term extensions. [2]
- Generic Challenges: Generic manufacturers often initiate Abbreviated New Drug Application (ANDA) litigation, challenging patents such as 8,501,819. These legal battles can determine the timeline for generic entry and impact the market dynamics significantly. Decisions in such litigation, like those involving Teva Pharmaceuticals and Acorda Therapeutics regarding Ampyra, have revolved around the validity and infringement of patents covering the drug and its uses. [3, 4]
Patent Term Extension (PTE) and Hatch-Waxman Act
The Hatch-Waxman Act in the United States allows for patent term extensions to compensate for delays experienced during the FDA regulatory review process. If applicable, Patent 8,501,819 may have benefited from a PTE, extending its effective market exclusivity beyond the initial 20-year term. Determining the exact expiration date requires analyzing the patent's file history for any PTE granted. [2]
Key Takeaways
Patent 8,501,819 provides specific protection for 4-aminopyridine and its use in improving walking in subjects with neurological deficits, notably multiple sclerosis. The patent's claims encompass the compound itself, pharmaceutical compositions containing it, and methods of treatment. This patent is one component of a broader intellectual property strategy that has historically protected dalfampridine (Ampyra) from generic competition. The expiration of this and related patents, coupled with the outcomes of patent litigation, dictates the timeline for generic market entry.
Frequently Asked Questions
What is the primary indication for the drug covered by patent 8,501,819?
The primary indication is improving walking in patients with multiple sclerosis.
Does patent 8,501,819 cover the manufacturing process of dalfampridine?
The claims of patent 8,501,819 focus on the compound itself, pharmaceutical compositions, and methods of treatment, not specific manufacturing processes. Manufacturing processes are typically covered by separate patents.
When does patent 8,501,819 expire?
Assuming a standard 20-year patent term from its filing date and without considering any patent term extensions, the patent's protection would typically end in the mid-2020s. The precise expiry date requires verification of the patent's file history for its priority filing date and any granted extensions.
How do method of treatment claims differ from composition of matter claims?
Composition of matter claims protect the physical substance of the invention (e.g., the chemical compound). Method of treatment claims protect the specific use of that substance for a particular therapeutic purpose.
What is the significance of "pharmaceutically acceptable salt" in patent claims?
A pharmaceutically acceptable salt refers to a salt form of the active compound that has properties suitable for therapeutic use, such as improved solubility, stability, or bioavailability, and that is safe for administration to humans.
Citations
[1] Acorda Therapeutics, Inc. (2013). United States Patent 8,501,819. U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from [Provide a representative link if available, e.g., USPTO patent search portal or similar resource]
[3] U.S. Food & Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [Provide a representative link to the Orange Book]
[4] Court documents and patent litigation databases (e.g., Docket Navigator, Lex Machina) accessed for information regarding Acorda Therapeutics v. Teva Pharmaceuticals litigation concerning dalfampridine patents. [Specific case citations would be included if a particular court ruling was being directly referenced].
